{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T08:06:09Z","timestamp":1779869169278,"version":"3.53.1"},"reference-count":42,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ther Adv Med Oncol"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Immune checkpoint inhibitors (ICIs) have shown limited efficacy in unselected advanced sarcomas. Drug-eluting bead transarterial chemoembolization (dTACE) may enhance antitumor immunity through localized chemotherapy and immunogenic cell death.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>This study aimed to evaluate the clinical benefits of combining dTACE with ICIs-based therapy in locally advanced or metastatic sarcomas.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>This was a retrospective study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>In this retrospective, exploratory cohort study (May 2019\u2013July 2024), patients receiving ICIs-based therapy (ICIs\u2009\u00b1\u2009chemotherapy\u2009\u00b1\u2009tyrosine kinase inhibitors) were stratified into two groups: systemic therapy alone (ICIs-based therapy) or combined with dTACE (ICIs-dTACE). Propensity score matching (PSM) was used to address selection bias and balance baseline characteristics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      A total of 213 patients were included (167 in the ICIs-based therapy group and 46 in the ICIs-dTACE group), yielding 44 matched pairs after PSM. The ICIs-dTACE group was associated with significantly superior median progression-free survival (PFS) compared to the ICIs-based therapy group (7.9 vs 4.5\u2009months; hazard ratio (HR)\u2009=\u20090.532, 95% confidence interval (CI) 0.339\u20130.836; log-rank\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.005). This association remained consistent after PSM (7.9 vs 4.7\u2009months; HR\u2009=\u20090.533, 95% CI 0.312\u20130.910; log-rank\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.019). The disease control rate was also higher in the ICIs-dTACE group both before (87.0% vs 71.9%,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.036) and after PSM (88.6% vs 70.5%,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.034). Multivariate analysis identified ICIs-dTACE as an independent predictor for improved PFS (post-PSM: HR\u2009=\u20090.522, 95% CI 0.284\u20130.959;\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.036). Notably, 16 patients (34.8%) in the ICIs-dTACE group underwent surgical resection, achieving an R0 resection rate of 87.5% (14\/16) and a major pathological response (\u2a7e90% necrosis) in 50.0% (8\/16). The safety profiles were comparable between groups, with grade \u2a7e3 adverse events (AEs) primarily attributable to chemotherapy. No grade 3 or higher AEs were attributed to dTACE.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>In this exploratory analysis, the addition of dTACE to ICIs-based therapy was associated with improved PFS and enabled surgical resection in a subset of patients with advanced sarcoma, without introducing additional severe toxicity. These findings suggest the synergistic potential of this combined modality and warrant prospective validation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/17588359261450424","type":"journal-article","created":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T10:27:04Z","timestamp":1779704824000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Drug-eluting bead transarterial chemoembolization combined with immune checkpoint inhibitors is associated with improved progression-free survival in locally advanced or metastatic sarcoma: a retrospective propensity score-matched analysis"],"prefix":"10.1177","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9751-5937","authenticated-orcid":false,"given":"Chenliang","family":"Zhou","sequence":"first","affiliation":[{"name":"Department of Oncology, Shanghai Sixth People\u2019s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongtao","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Oncology, Shanghai Sixth People\u2019s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guowei","family":"Qian","sequence":"additional","affiliation":[{"name":"Department of Oncology, Shanghai Sixth People\u2019s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxi","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Oncology, Shanghai Sixth People\u2019s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuier","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Oncology, Shanghai Sixth People\u2019s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200233, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zan","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Oncology, Shanghai Sixth People\u2019s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200233, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3529-6951","authenticated-orcid":false,"given":"Yonggang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Shanghai Sixth People\u2019s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200233, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,5,25]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.32074\/1591-951X-213"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.08.1995"},{"key":"e_1_3_4_4_2","first-page":"625","article-title":"Developments in systemic therapy for soft tissue and bone sarcomas","volume":"17","author":"George S.","year":"2019","unstructured":"George S. Developments in systemic therapy for soft tissue and bone sarcomas. J Natl Compr Canc Netw 2019; 17: 625\u2013628.","journal-title":"J Natl Compr Canc Netw"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-023-14702-x"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-018-6658-4"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.625226"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30153-6"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2303383"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30624-1"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.04.034"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-25-0491"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001561"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.3689"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-017-2530-3"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00270-016-1399-x"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004205"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102622"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.940009"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.03.141"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-025-01698-9"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12328-021-01569-2"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1080\/00273171.2011.568786"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-147-8-200710160-00010-w1"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2022.0035"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1097\/JS9.0000000000001378"},{"key":"e_1_3_4_27_2","first-page":"14","article-title":"Primary osteogenic sarcoma: pathologic aspects in 20 patients after treatment with chemotherapy en bloc resection, and prosthetic bone replacement","volume":"101","author":"Huvos AG","year":"1977","unstructured":"Huvos AG, Rosen G, Marcove RC. Primary osteogenic sarcoma: pathologic aspects in 20 patients after treatment with chemotherapy en bloc resection, and prosthetic bone replacement. Arch Pathol Lab Med 1977; 101: 14\u201318.","journal-title":"Arch Pathol Lab Med"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2015.09.021"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyad052"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.1617"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2019.07.018"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000798"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00816-4"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-024-01030-z"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2016.107"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aae0105"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-032712-100008"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13569-018-0096-8"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15030700"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00274-1"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10434-999-0057-9"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000000774"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-025-11365-y"}],"container-title":["Therapeutic Advances in Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17588359261450424","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17588359261450424","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17588359261450424","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T07:46:36Z","timestamp":1779867996000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17588359261450424"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":42,"alternative-id":["10.1177\/17588359261450424"],"URL":"https:\/\/doi.org\/10.1177\/17588359261450424","relation":{},"ISSN":["1758-8359","1758-8359"],"issn-type":[{"value":"1758-8359","type":"print"},{"value":"1758-8359","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]},"article-number":"17588359261450424"}}